Nektar Therapeutics | NKTR - Current Liabilities


Nektar Therapeutics reported $53.54M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amgen USD 24.96B 534M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3B 350.5M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Cipla INR 70.14B 7.16B Mar/2026
Dr.Reddys Laboratories INR 167.47B 9.16B Mar/2026
Eisai JPY 340.25B 47.42B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Exelixis USD 370.98M 34.67M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Takeda JPY 2.43T 180.65B Mar/2026
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026